A dual functional ruthenium arene complex induces differentiation and apoptosis of acute promyelocytic leukemia cells
Related Experiment Video
Updated: Dec 28, 2025
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Hai Huang1, Kaiming Cao1, Yaqiong Kong2
1CAS Key Laboratory of Soft Matter Chemistry , Department of Chemistry , University of Science and Technology of China , Hefei , Anhui 230026 , China .
Abstract:
Human acute promyelocytic leukemia (APL) is the most malignant form of acute leukemia. The fusion of PML and RARα genes is responsible for over 98% of cases of APL. In this work, we found that a Ru(ii) arene complex, [(η6-p-bip)Ru(en)Cl][PF6] (Ru-1), can selectively react with PML, leading to zinc-release and protein unfolding. Consequently, the degradation of the fusion protein PML-RARα occurs, which causes the differentiation of APL cells. In addition, Ru-1 can also bind to DNA and trigger apoptosis of APL cells. Therefore, Ru-1 acts as a dual functional agent that inhibits the growth of APL cells and induces cell differentiation. In contrast, the other non-selective Ru(ii) compound, though also highly reactive to PML, does not exhibit anti-APL activity. The selectivity of Ru-1 to PML suggests a new strategy for the development of anti-APL drugs using ruthenium agents.
Insights
A novel ruthenium complex, Ru-1, selectively targets the PML protein in acute promyelocytic leukemia (APL). This targeted action degrades the fusion protein, inducing APL cell differentiation and apoptosis for a dual therapeutic effect.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Human acute promyelocytic leukemia (APL) is a severe hematologic malignancy.
- The PML-RARα fusion protein drives APL development in over 98% of cases.
Purpose of the Study:
- To investigate the therapeutic potential of a selective ruthenium(II) arene complex, Ru-1, against APL.
- To elucidate the mechanism of action of Ru-1 in APL cells.
Main Methods:
- Synthesis and characterization of the ruthenium(II) arene complex Ru-1.
- In vitro studies assessing Ru-1's reactivity with PML and PML-RARα.
- Evaluation of Ru-1's effects on APL cell differentiation, apoptosis, and proliferation.
- Comparative analysis with a non-selective ruthenium compound.
Main Results:
- Ru-1 selectively reacts with the PML protein, causing zinc release and unfolding.
- This interaction leads to the degradation of the PML-RARα fusion protein, inducing APL cell differentiation.
- Ru-1 also exhibits DNA-binding activity, triggering apoptosis in APL cells.
- Selective Ru-1 demonstrated significant anti-APL activity, unlike a non-selective ruthenium compound.
Conclusions:
- Ru-1 functions as a dual-acting agent, inhibiting APL cell growth and inducing differentiation.
- The selectivity of Ru-1 towards PML offers a promising new strategy for developing ruthenium-based anti-APL therapeutics.
More Related Videos
09:16Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
02:23Abnormal Proliferation
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...